Axon 1738
CAS [155148-31-5]
MF C28H54N8.8HClMW 794.47
E De Clercq et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. agents chemother. 1994, 38(4), 668–74. |
SL Davies et al. Plerixafor Hydrochloride. Drugs Fut. 2007,32(2), 123. |
AF Cashen et al. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncol. 2007, 3(1), 19–27. |
G Calandra et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin"s lymphoma, Hodgkin"s disease and multiple myeloma patients previously failing mobilization with chemotherapy (...). Bone Marrow Transpl. 2008, 41, 331–338. |
1,4-bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene octahydrochloride
[110078-46-1]
Axon Medchem的业务之一,是独有的Axon Ligands配体库,在世界范围内,被认为是药物研发的标准。这其中,针对850余种生物靶标(包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等),Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库,Axon Medchem还是欧洲著名的CRO公司,主要针对生物活性分子和药物类似分子展开合成及协议开发工作,在过去的10年中,Axon Medchem已经发现了多种潜在药物分子,并在生物医药界享有一定的声誉。